Core Insights - Shares of Xenon Pharmaceuticals (XENE) have increased by approximately 20% over the past three months, primarily due to positive top-line data from the X-TOLE2 study evaluating azetukalner for focal onset seizures (FOS) [1][6] Group 1: Clinical Development - Azetukalner is being evaluated in late-stage studies for the treatment of FOS, with two identical phase III studies, X-TOLE2 and X-TOLE3, assessing 15 mg or 25 mg doses administered with food as an adjunctive treatment [2][4] - The X-TOLE2 study met its primary endpoint, demonstrating a median percent change in monthly FOS frequency from baseline to week 12 for both doses compared to placebo [3] - Azetukalner's clinical profile is differentiated from existing antiseizure therapies, featuring no titration requirement, convenient once-daily dosing, and minimal risk of drug-drug interactions [3] Group 2: Regulatory and Market Outlook - Xenon plans to submit a new drug application to the FDA for azetukalner in Q3 2026, with management highlighting the favorable safety profile and ease of use as key factors for its potential as a preferred treatment for uncontrolled seizures [4] - The ongoing phase III X-TOLE3 study is expected to support regulatory filings in international markets, enhancing the global commercial opportunity for azetukalner [5] Group 3: Broader Pipeline and Future Studies - Azetukalner is also being developed for other neurological disorders, including major depressive disorder (MDD) and bipolar depression (BPD), with top-line data from the X-NOVA2 study expected in the first half of 2027 [7] - The company is conducting a phase III X-ACKT study for azetukalner in primary generalized tonic-clonic seizures, which is currently enrolling patients [8] - Xenon has initiated early-stage studies for other pipeline assets, including XEN1120 and XEN1701, targeting Kv7 and Nav1.7 for various therapeutic indications [9]

Core Viewpoint - Xenon Pharmaceuticals Inc. has experienced a significant stock increase of 31.7% week-on-week, driven by positive clinical trial results for its epilepsy and depression treatment candidate, Azetukalner, and plans to submit a new drug application (NDA) in the latter half of the year [1][4]. Group 1: Clinical Trial Results - The third phase of the clinical trial for Azetukalner demonstrated a 53% reduction in seizures among patients taking 25mg and 15mg doses compared to the placebo over a 12-week period [4]. - Azetukalner exhibited a safety and tolerability profile consistent with previous studies, reinforcing its potential as a treatment option [4]. Group 2: Financial Developments - Following the positive trial results, the company successfully raised $747.5 million through a public offering of 12.2 million common shares [5]. - The announcement of the NDA submission for Azetukalner to the FDA is planned for the third quarter of the year [2]. Group 3: Management Commentary - The President and CEO of Xenon Pharmaceuticals, Ian Mortimer, expressed satisfaction with the trial data, stating it exceeded expectations and showcased the highest placebo-adjusted efficacy observed in a pivotal epilepsy study [5].

Core Insights - Shares of Xenon Pharmaceuticals (XENE) increased by 49.6% following the announcement of positive top-line data from the phase III X-TOLE2 study for azetukalner, aimed at treating focal onset seizures (FOS) [1] Study Results - The X-TOLE2 study assessed the efficacy, safety, and tolerability of azetukalner at doses of 15 mg and 25 mg, administered with food as an add-on treatment for FOS patients [2] - The study achieved its primary endpoint, demonstrating a median percent change (MPC) in monthly FOS frequency from baseline to week 12 for both doses compared to placebo [2] - The placebo-adjusted MPC for the 25 mg group was -42.7%, an improvement over the -34.6% observed in the earlier phase IIb X-TOLE study [3] - Azetukalner was generally well-tolerated, exhibiting a safety profile consistent with previous studies [3] Future Plans - Xenon intends to submit a new drug application (NDA) to the FDA for azetukalner to treat FOS in Q3 2026 [3][7] - The company is also conducting the phase III X-TOLE3 study for azetukalner in FOS, which is currently enrolling patients to support regulatory submissions in markets outside the U.S. [6] Competitive Position - If approved, azetukalner would be the only KV7 potassium channel opener available for epilepsy treatment, supported by its favorable safety profile and differentiated mechanism [8] - Besides FOS, azetukalner is being developed for other neurological disorders, including major depressive disorder (MDD) and bipolar depression (BPD) [9] Clinical Development - Xenon is conducting two phase III studies, X-NOVA2 and X-NOVA3, for azetukalner in MDD, with top-line data from X-NOVA2 expected in the first half of 2027 [10] - The first of two phase III studies, X-CEED, for azetukalner in BPD is also ongoing [10] Stock Performance - Over the past six months, Xenon's shares have increased by 68.6%, outperforming the industry average increase of 14.3% [4]

Core Viewpoint - NeuroPace, Inc. is set to present at the Leerink 2026 Global Healthcare Conference, highlighting its focus on transforming the lives of individuals with epilepsy through innovative medical devices [1] Company Overview - NeuroPace, Inc. is based in Mountain View, California, and specializes in medical devices aimed at reducing or eliminating seizures in epilepsy patients [1] - The company’s RNS System is the first and only commercially available brain-responsive platform that provides personalized, real-time treatment at the source of seizures [1] Financial Performance - For the fourth quarter of 2025, NeuroPace reported total revenue of $26.6 million, marking a 24% increase compared to the fourth quarter of 2024 [1] - Revenue from the RNS System reached $22.4 million, reflecting a growth of 26% compared to the same period in the previous year [1]

Q4 & FY 2025 Financial Results & Business Update February 24, 2026 Copyright © 2026 Harmony Biosciences. All rights reserved. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2025 net product revenue, expectations ...

Core Message - NeuroPace aims to transform the lives of individuals suffering from epilepsy by reducing or eliminating debilitating seizures, which is central to the company's mission and decision-making process [3]. Company Overview - NeuroPace is represented by CEO Joel Becker, who emphasizes the company's commitment to patients and clinicians involved in epilepsy care [2][3]. - The company is led by a strong team dedicated to its mission and operational goals [4].

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Azetukalner Efficacy and Safety - Azetukalner demonstrated a 90.9% median percent change (MPC) reduction in monthly focal onset seizure (FOS) frequency after 48 months in the open-label extension (OLE) [92] - A subset of patients receiving 1-2 anti-seizure medications (ASMs) at double-blind period (DBP) baseline experienced a 100% monthly reduction in FOS frequency [92] - 38% of patients treated with azetukalner for at least 48 months achieved seizure freedom for one year or longer [92] - Azetukalner's safety and tolerability profile in the OLE remained consistent with the DBP [92, 73] - In the Phase 2b X-TOLE study, azetukalner showed statistically significant and dose-dependent seizure reduction, with up to a 52.8% median percent change from baseline [34] Commercial Opportunity and Market Insights - Xenon Pharmaceuticals has $555.3 million in cash, cash equivalents, and marketable securities as of September 30, 2025, with anticipated cash runway into 2027 [18] - An estimated 2.6 million adults in EU4 + UK, 3.0 million in Japan, and 0.8 million in the U.S have diagnosed epilepsy [95] - Focal onset seizures (FOS) represent the largest segment of the epilepsy population [95] - Up to 50% of epilepsy patients may require additional treatment options, presenting a significant commercial opportunity [102, 97] Clinical and Patient Burden - Depression is a significant burden for patients with FOS, highlighting the need for therapeutics that do not exacerbate mood disorders [92, 79] - Titration of anti-seizure medications (ASMs) poses a significant burden for both patients and healthcare professionals (HCPs), underscoring the need for simplified or no-titration ASMs [92, 87]

Company Overview - Harmony Biosciences Holdings, Inc. is focused on developing and commercializing innovative therapies for patients with rare neurological diseases, particularly those with unmet medical needs [10] - The company was established in 2017 and is headquartered in Plymouth Meeting, Pennsylvania [10] Product Development - The company is conducting a Phase 3 ARGUS trial for EPX-100 (clemizole hydrochloride) aimed at treating Dravet syndrome, showing clinically meaningful reductions in seizure activity [1][3] - EPX-100 is also being evaluated in the Phase 3 LIGHTHOUSE trial for Lennox-Gastaut syndrome, both trials being global, multicenter, randomized, double-blind, placebo-controlled studies [3] Clinical Trial Results - Initial open-label extension data from the ARGUS trial indicated a median reduction of approximately 50% in countable motor seizure frequency per 28 days, with 50% of participants achieving at least a 50% reduction [8] - The treatment was generally well-tolerated, with the most common adverse events being seizures, pyrexia, and upper respiratory tract infections, while gastrointestinal adverse events were minimal [8] Future Outlook - The company anticipates advancing its epilepsy franchise and is progressing towards topline data readout from the ARGUS trial expected in 2026 [3]

Core Insights - Praxis Precision Medicines presented significant clinical updates at the American Epilepsy Society Annual Meeting, highlighting the potential of relutrigine and vormatrigine in treating epilepsy [2][3] Group 1: Relutrigine for Developmental and Epileptic Encephalopathies (DEEs) - The EMBOLD study demonstrated a 53% placebo-adjusted reduction in seizures (p < 0.0002) and a 66% increase in motor seizure-free days (p = 0.034) [8] - Relutrigine was well-tolerated, showing rapid and significant seizure reduction over time, with broad functional improvements in behavior, alertness, communication, and overall status [4][8] - The company plans to meet with the FDA to discuss the next steps for the New Drug Application (NDA) [4] Group 2: Vormatrigine for Focal Onset Seizures (FOS) and Generalized Epilepsy - The RADIANT study indicated a 54% median reduction in seizures for patients taking vormatrigine over 8 weeks, with 58% achieving at least a 50% reduction in week 1, increasing to 61% by week 8 [9] - FOS patients reached a 100% median weekly seizure reduction after 8 weeks, maintained through 16 weeks, with over 11% experiencing seizure freedom for the entire 8-week period [9] - Vormatrigine is positioned as a best-in-class therapy with fast-acting efficacy, sustained reduction, and favorable safety profiles [5] Group 3: Company Commitment and Future Studies - The company is committed to accelerating treatment options for patients and advancing the broader DEE study, EMERALD, along with ASO programs and FOS studies toward registration [3] - Praxis has completed recruitment for the POWER1 pivotal study in FOS and is on track to complete the POWER2 study in the second half of 2026, with the POWER3 study set to begin in the first half of 2026 [10]